Results 121 to 130 of about 2,071 (176)

Bimekizumab for plaque psoriasis

, 2022
openaire   +1 more source

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

JAMA Dermatol
Augustin M, Feldman SR, Warren RB, Armstrong A, Vender R, López-Ferrer A, Dawe WH, Lambert J, Szilagyi B, Hoepken B, Warham R, Gottlieb AB.   +11 more
europepmc   +1 more source

"Efficacy and safety of bimekizumab in moderate-to-severe hidradenitis suppurativa: A systematic review and meta-analysis of RCTs". [PDF]

Medicine (Baltimore)
Assiri A, Almahdi M, Mobarki O, Sumayli R, Alharbi N, Alharbi W, Alhazmi S, Alghamdi A, Alturkistani M.   +8 more
europepmc   +1 more source

Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies. [PDF]

Rheumatol Adv Pract
Tillett W, Gossec L, Husni ME, Morita A, Ink B, Bajracharya R, Healy P, Mørup MF, Walsh JA.   +8 more
europepmc   +1 more source

Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study. [PDF]

Dermatol Ther (Heidelb)
Tada Y, Kagitani H, Kimura S, Tsujimoto N, Mochizuki K.   +4 more
europepmc   +1 more source

Efficacy of Biologics for Hidradenitis Suppurativa: A Network Meta Analysis and Meta Regression for Baseline Disease Severity. [PDF]

Australas J Dermatol
Pham J, Sholji T, Aghajani M, Maye E, Burrell K, Kok C, Frew JW.   +6 more
europepmc   +1 more source

Modalities of Combined Medical and Surgical Treatment in Hidradenitis Suppurativa: A Systematic Review of Efficacy and Safety. [PDF]

Dermatol Ther (Heidelb)
Mateu-Arrom L, Molina-Leyva A, Vilarrasa E.   +2 more
europepmc   +1 more source

Drug reaction with eosinophilia and systemic symptoms syndrome secondary to bimekizumab. [PDF]

JAAD Case Rep
Fray K, Petrou IA, O'Callaghan D.
europepmc   +1 more source

Auricular and periauricular hidradenitis suppurativa: Increasing awareness of atypical sites. [PDF]

SAGE Open Med Case Rep
Fortman C, Seiter D.
europepmc   +1 more source

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System. [PDF]

JAAD Int
Alomary SA, Baker NJ, Ogunleye T, Taylor SC.   +3 more
europepmc   +1 more source